secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0000950170-23-018076
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Q1 core revenue rises 150% to $62.7M; raises FY2023 core revenue guidance to $250M
--------------------------------------------------------------------------------

- Total revenue $66.2M; core revenue (ex-COVID) $62.7M, up 150% YoY, a record.
- GAAP net loss $15.3M ($0.52 loss per share); non-GAAP net loss $6.5M ($0.22 loss per share).
- Adjusted EBITDA loss of $7.2M for Q1 2023.
- Cash, cash equivalents, and marketable securities of $867.8M as of March 31, 2023.
- Raises full-year 2023 core revenue guidance to $250 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017023018076/0000950170-23-018076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017023018076/flgt-20230505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-018076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer